Synthetic Biologics Inc (SYN) 2.59 $SYN
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 8:16AM CDT
GES: 18.84 (-0.58), SYN: 2.59 (+0.06), SMLR: 4.65 (-0.12), SQM: 18.86 (+0.99), PWE: 1.51 (unch), RMGN: 1.45 (-0.01), CNDO: 3.90 (-0.31), CBMX: 2.07 (-0.03), NBG: 1.34 (+0.14), NQ: 3.74 (-0.15), CNCE: 14.76 (unch), FOLD: 11.61 (-0.85)
Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection
PR Newswire - Thu Mar 19, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive pharmacokinetics (PK) results from both the Phase 1a and 1b studies of SYN-004, which is being developed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Synthetic Biologics' (SYN) CEO Jeff Riley on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 16, 11:15AM CDT
SYN: 2.59 (+0.06)
Stocks Coverage on the Health Care Sector - AstraZeneca, Novartis, Raptor Pharma, Synthetic Biologics, and BioDelivery Sciences Intl.
PR Newswire - Mon Mar 16, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BDSI: 14.97 (-0.25), SYN: 2.59 (+0.06), RPTP: 11.86 (+0.14), AZN: 72.70 (+1.80), NVS: 101.68 (+1.81)
Synthetic Biologics FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:26AM CDT
SYN: 2.59 (+0.06)
Synthetic Biologics reports FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 6:02AM CDT
SYN: 2.59 (+0.06)
Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights
PR Newswire - Mon Mar 16, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today reported financial results for the year ended December 31, 2014, and provided an operational update.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.59 (+0.06), ZIOP: 13.89 (-0.11), UNIS: 3.63 (-0.01), FCSC: 5.48 (-0.14), XON: 46.11 (-1.26), MNKD: 5.26 (-0.28)
Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 14.97 (-0.25), VRTX: 131.00 (-3.25), CERU: 10.25 (-0.41), FOMX: 10.00 (+0.10), ONTX: 2.57 (-0.03), PFNX: 14.73 (+0.06), OMER: 24.94 (-0.43), PGNX: 6.06 (-0.45), SYN: 2.59 (+0.06), VCYT: 7.31 (-0.99), STEM: 1.03 (-0.03), APRI: 2.08 (+0.04), KPTI: 31.44 (-1.61)
Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015
PR Newswire - Wed Mar 11, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-004, the Company's candidate therapy designed to degrade intravenous (IV) antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, will be presented during Digestive Disease Week® (DDW) 2015 in Washington DC on May 16-19.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 11:45AM CDT
HTBX: 6.82 (-0.17), CTRV: 3.30 (-0.40), AKRX: 49.03 (-0.41), BRSS: 15.59 (+0.43), CASI: 1.46 (-0.05), JOB: 0.92 (-0.04), LL: 28.51 (-0.84), MIND: 4.91 (+0.05), BBNK: 26.62 (+0.36), WPRT: 4.15 (+0.02), URBN: 47.01 (+0.31), OCC: 4.31 (-0.06), SYN: 2.59 (+0.06), IDT: 17.02 (-0.51), GERN: 3.98 (-0.15), TITN: 13.31 (+0.10), IMPV: 44.61 (-0.28), NNBR: 23.64 (+0.94), REPH: 8.64 (+0.49), VPCO: 1.13 (-0.03)
Synthetic Biologics to Report Year End 2014 Financial Results
PR Newswire - Mon Mar 09, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that the Company intends to release its financial results for the year ended December 31, 2014 on Monday, March 16, 2015. The Company will also hold an investor conference call on Monday, March 16th, at 8:30 a.m. EDT.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Synthetic Biologics to Present at the 27th Annual ROTH Conference
PR Newswire - Tue Mar 03, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, Chief Executive Officer, is scheduled to present at the 27th Annual ROTH Conference being held on March 8-11, 2015 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time).
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015
PR Newswire - Mon Mar 02, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-005 for the treatment of Pertussis will be highlighted at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), April 25-28, in Copenhagen, Denmark. Two posters will be presented under the Respiratory Infections category all four days at ECCMID on 50 ePoster stations, as follows:
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Synthetic Biologics (SYN) Jumps: Stock Up 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 17, 8:11AM CST
Synthetic Biologics Inc. (SYN) was a big mover last session, as the company saw its shares rise over 9% on the day.
SYN: 2.59 (+0.06), BMRN: 125.17 (-2.32)
Synthetic Biologics Announces Poster Presentation of C-IBS Candidate Therapy Data at Digestive Disease Week® 2015
PR Newswire - Tue Feb 17, 5:56AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-010, the Company's candidate therapy to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), will be presented during Digestive Disease Week® (DDW) 2015 in Washington DC on May 16-19. The research was performed at Cedars-Sinai Medical Center under the direction of Mark Pimentel, MD, Director of Cedars-Sinai's GI Motility Program and Laboratory, and Chairman of Synthetic Biologics' C-IBS Clinical Advisory Board.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Synthetic Biologics Unveils Phase Ib Safety Data on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 12:30PM CST
Synthetic Biologics, Inc. (SYN) announced positive top-line results from phase Ib study on SYN-004.
SYN: 2.59 (+0.06), BMRN: 125.17 (-2.32), ALNY: 117.46 (-2.24)
Synthetic Biologics: A Speculative Small Cap Packed With Power
Jerad W. Starr - Seeking Alpha - Tue Feb 10, 8:19AM CST
I reserve a portion of my portfolio for small biotechnology companies. Those who invest in this sector know that these stocks are very volatile and can rise or fall 50% on major news or trial results. With that in mind, I believe one can typically...
SYN: 2.59 (+0.06), TEVA: 62.10 (+0.55)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 8:16AM CDT
GES: 18.84 (-0.58), SYN: 2.59 (+0.06), SMLR: 4.65 (-0.12), SQM: 18.86 (+0.99), PWE: 1.51 (unch), RMGN: 1.45 (-0.01), CNDO: 3.90 (-0.31), CBMX: 2.07 (-0.03), NBG: 1.34 (+0.14), NQ: 3.74 (-0.15), CNCE: 14.76 (unch), FOLD: 11.61 (-0.85)
Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection
PR Newswire - Thu Mar 19, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive pharmacokinetics (PK) results from both the Phase 1a and 1b studies of SYN-004, which is being developed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Synthetic Biologics' (SYN) CEO Jeff Riley on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 16, 11:15AM CDT
SYN: 2.59 (+0.06)
Stocks Coverage on the Health Care Sector - AstraZeneca, Novartis, Raptor Pharma, Synthetic Biologics, and BioDelivery Sciences Intl.
PR Newswire - Mon Mar 16, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BDSI: 14.97 (-0.25), SYN: 2.59 (+0.06), RPTP: 11.86 (+0.14), AZN: 72.70 (+1.80), NVS: 101.68 (+1.81)
Synthetic Biologics FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 7:26AM CDT
SYN: 2.59 (+0.06)
Synthetic Biologics reports FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 6:02AM CDT
SYN: 2.59 (+0.06)
Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights
PR Newswire - Mon Mar 16, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today reported financial results for the year ended December 31, 2014, and provided an operational update.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.59 (+0.06), ZIOP: 13.89 (-0.11), UNIS: 3.63 (-0.01), FCSC: 5.48 (-0.14), XON: 46.11 (-1.26), MNKD: 5.26 (-0.28)
Next Week In Biotech: Vertex PDUFA, Organon Ad Comm
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 14.97 (-0.25), VRTX: 131.00 (-3.25), CERU: 10.25 (-0.41), FOMX: 10.00 (+0.10), ONTX: 2.57 (-0.03), PFNX: 14.73 (+0.06), OMER: 24.94 (-0.43), PGNX: 6.06 (-0.45), SYN: 2.59 (+0.06), VCYT: 7.31 (-0.99), STEM: 1.03 (-0.03), APRI: 2.08 (+0.04), KPTI: 31.44 (-1.61)
Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015
PR Newswire - Wed Mar 11, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-004, the Company's candidate therapy designed to degrade intravenous (IV) antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, will be presented during Digestive Disease Week® (DDW) 2015 in Washington DC on May 16-19.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 11:45AM CDT
HTBX: 6.82 (-0.17), CTRV: 3.30 (-0.40), AKRX: 49.03 (-0.41), BRSS: 15.59 (+0.43), CASI: 1.46 (-0.05), JOB: 0.92 (-0.04), LL: 28.51 (-0.84), MIND: 4.91 (+0.05), BBNK: 26.62 (+0.36), WPRT: 4.15 (+0.02), URBN: 47.01 (+0.31), OCC: 4.31 (-0.06), SYN: 2.59 (+0.06), IDT: 17.02 (-0.51), GERN: 3.98 (-0.15), TITN: 13.31 (+0.10), IMPV: 44.61 (-0.28), NNBR: 23.64 (+0.94), REPH: 8.64 (+0.49), VPCO: 1.13 (-0.03)
Synthetic Biologics to Report Year End 2014 Financial Results
PR Newswire - Mon Mar 09, 5:57AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that the Company intends to release its financial results for the year ended December 31, 2014 on Monday, March 16, 2015. The Company will also hold an investor conference call on Monday, March 16th, at 8:30 a.m. EDT.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Synthetic Biologics to Present at the 27th Annual ROTH Conference
PR Newswire - Tue Mar 03, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, Chief Executive Officer, is scheduled to present at the 27th Annual ROTH Conference being held on March 8-11, 2015 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time).
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015
PR Newswire - Mon Mar 02, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-005 for the treatment of Pertussis will be highlighted at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), April 25-28, in Copenhagen, Denmark. Two posters will be presented under the Respiratory Infections category all four days at ECCMID on 50 ePoster stations, as follows:
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Synthetic Biologics (SYN) Jumps: Stock Up 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 17, 8:11AM CST
Synthetic Biologics Inc. (SYN) was a big mover last session, as the company saw its shares rise over 9% on the day.
SYN: 2.59 (+0.06), BMRN: 125.17 (-2.32)
Synthetic Biologics Announces Poster Presentation of C-IBS Candidate Therapy Data at Digestive Disease Week® 2015
PR Newswire - Tue Feb 17, 5:56AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-010, the Company's candidate therapy to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), will be presented during Digestive Disease Week® (DDW) 2015 in Washington DC on May 16-19. The research was performed at Cedars-Sinai Medical Center under the direction of Mark Pimentel, MD, Director of Cedars-Sinai's GI Motility Program and Laboratory, and Chairman of Synthetic Biologics' C-IBS Clinical Advisory Board.
SYN: 2.59 (+0.06), XON: 46.11 (-1.26)
Synthetic Biologics Unveils Phase Ib Safety Data on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 12:30PM CST
Synthetic Biologics, Inc. (SYN) announced positive top-line results from phase Ib study on SYN-004.
SYN: 2.59 (+0.06), BMRN: 125.17 (-2.32), ALNY: 117.46 (-2.24)
Synthetic Biologics: A Speculative Small Cap Packed With Power
Jerad W. Starr - Seeking Alpha - Tue Feb 10, 8:19AM CST
I reserve a portion of my portfolio for small biotechnology companies. Those who invest in this sector know that these stocks are very volatile and can rise or fall 50% on major news or trial results. With that in mind, I believe one can typically...
SYN: 2.59 (+0.06), TEVA: 62.10 (+0.55)
